CAR-T therapy is a major advance in cancer care, but high costs and centralized global manufacturing limit access.

Autolus Therapeutics is working with Cellares to assess automated CAR T manufacturing to support rising demand for its ...

Patients treated in an outpatient setting who later required admission spent an average of 12.1 days in the hospital, ...

Next-generation automation is closing the gap between curative science and real-world demand, enabling faster development, ...

Improved QOL is observed in patients over two years post-infusion and those without disease progression, highlighting the ...

Please provide your email address to receive an email when new articles are posted on . After first generating excitement in late 2022, this year was a bonanza for news about chimeric antigen receptor ...

H 2026 Catalyst Stack Anticipated to Validate Scalable, Off-the-Shelf CAR T in Oncology and Autoimmune Disease Interim Futility Analysis of MRD ...

Chimeric antigen receptor (CAR)-T cells and T-cell therapies have been used in the treatment of various cancers for several years. In a review published in JAMA, a research team led by Christian ...

Renier Brentjens, MD, PhD, one of the pioneers in the development of chimeric antigen receptor (CAR) T-cell therapy, is poised to see the technology take its next big leap, with researchers testing ...

CAR T-cell therapy, which transforms patients’ own immune cells into cancer-fighting warriors, has revolutionized how physicians treat cancer, especially blood cancers. “These patients can be cured ...

As demand for precision medicine accelerates, CAR T and CAR Treg cell therapies are emerging as crucial tools in the fight against cancer and autoimmune diseases. For Thomas Fellner, PhD, head of ...